secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001193125-26-048873
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics Q4 2025 net loss $130.6M; CASGEVY Q4 revenue $54M, full year $116M
--------------------------------------------------------------------------------

- Net loss of $130.6M in Q4 2025 vs $37.3M loss in Q4 2024; collaboration expense increased to $53.7M.
- CASGEVY revenue $54M in Q4, $116M full year 2025; 64 patients infused during the year (30 in Q4).
- Cash, cash equivalents and marketable securities $1,975.8M as of Dec 31, 2025, vs $1,903.8M Dec 31, 2024.
- R&D expenses $83.5M (Q4 2025) vs $71.7M (Q4 2024); G&A $18.4M vs $18.1M.
- Pediatric CASGEVY submissions for ages 5-11 expected H1 2026; in vivo programs CTX460 (mid-2026) and CTX340 (H1 2026) to enter clinic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526048873/0001193125-26-048873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000119312526048873/crsp-20260212.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-048873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer